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Abstract Both the porcine K2A-adrenoceptor and a fusion
protein between this receptor and a pertussis toxin-resistant form
of Gi1K were stably expressed in Rat-1 fibroblasts. The agonist
UK14304 mediated a biphasic regulation of adenylyl cyclase
activity via the isolated receptor with inhibition of the enzyme
activity at low concentrations of the compound which was
subsequently reversed at higher concentrations. By contrast,
stimulation of the fusion protein with this agonist could only
produce inhibition of enzyme activity. This inhibition was
produced by activation of endogenous Gi rather than the fused
K subunit of Gi1, as pertussis toxin treatment obliterated
inhibitory regulation of adenylyl cyclase via the fusion construct.
Pertussis toxin treatment potentiated stimulation of adenylyl
cyclase via the isolated receptor but such treatment was unable to
uncover capacity of the fusion protein to produce such an effect.
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1. Introduction
A number of G protein-coupled receptors (GPCRs) have
the capacity to interact with multiple guanine nucleotide bind-
ing proteins (G proteins) and thus regulate more than one
e¡ector pathway [1,2]. Furthermore, certain GPCRs have
the capacity to interact with G proteins which have opposite
e¡ects on the same e¡ector pathway [3,4].
Although the K2A-adrenoceptor is one prototypic example
of a GPCR which interacts with the Gi-family of G proteins
to produce inhibition of adenylyl cyclase (AC) activity [5,6], a
number of studies have noted the capacity of this GPCR to
interact also with Gs. This receptor is then able, particularly
when expressed at high levels and in the presence of high
concentrations of certain agonists, to stimulate AC activity
[7,8]. Such observations suggest that the e¡ectiveness of ago-
nists at this receptor may vary between di¡erent cells and
tissues.
Receptor knock-out studies in mice indicate that the K2A-
adrenoceptor is a key element in the central control of sym-
pathetic out£ow, as it mediates the central hypotensive re-
sponse to K2-adrenoceptor agonists [9,10]. Using such trans-
genic models it has been shown that the K2A-adrenoceptor is
also the major contributor to the analgesic e¡ects of K2-adre-
noceptor agonists [11].
We have recently generated a fusion protein between the
porcine K2A-adrenoceptor and a pertussis toxin-resistant
(C351G) mutant of the K subunit of Gi1. Following stable
expression of this construct in Rat-1 ¢broblasts, we observed
that a range of K2-adrenoceptor agonists were able to stimu-
late high a⁄nity GTPase activity in membranes of these cells.
This e¡ect was produced via both the receptor-linked and
endogenous GiK G proteins [12].
Herein we demonstrate that although the free porcine K2A-
adrenoceptor can interact with GsK, the fusion construct pre-
vents interaction of the receptor with this G protein resulting
in a situation in which UK14304 can only mediate inhibition
of AC activity.
2. Materials and methods
2.1. Materials
All tissue culture reagents were from Sigma or Life Technologies
(Paisley, Scotland). [3H]Adenine (15^20 Ci/mmol) and [3H]RS-79948-
197 (80^90 Ci/mmol) were purchased from Amersham Pharmacia Bio-
tech. All other chemicals were from Sigma or Fison and were of the
highest purity available.
2.2. Cell culture
Ragi 77 [12], Tag WT [13], as well as parental Rat-1 ¢broblast cells
were cultured in DMEM containing 10% (v/v) newborn calf serum, in
a 5% CO2 atmosphere at 37‡C. Two days before the AC assays, cells
were plated in 12-well plates to obtain full con£uency on the day of
assay. For binding measurements cells were plated on 10-cm tissue
culture dishes.
In some experiments cells were treated with 25 ng/ml of pertussis
toxin or 1 Wg/ml of cholera toxin 16 h before assay.
2.3. Whole cell binding
Cells were grown to con£uency in 10-cm tissue culture dishes. They
were harvested in 2 ml of 0.5 mM EDTA in PBS, centrifuged at
1000Ug and washed twice with PBS. The ¢nal pellet was then gently
resuspended in binding bu¡er (75 mM Tris-HCl, pH 7.4, 1 mM
EDTA, 12.5 mM MgCl2). An aliquot of cells was counted and the
cells diluted with binding bu¡er to obtain approximately 200 000 cells/
assay.
Cells were incubated with a saturating concentration of
[3H]RS79948-197 (2 nM) [14] for 1 h at 30‡C in the presence or
absence of 1U1034 M idazoxan (non-speci¢c binding). Binding was
terminated by ¢ltration through GF/C membranes using a Brandel
cell harvester. Free radioactivity was removed by 3U5-ml washes of
cold TE bu¡er (75 mM Tris-HCl, pH 7.4, 1 mM EDTA). Filters were
soaked in scintillant £uid and counted in a liquid scintillation counter.
The apparent number of receptor/cell was then calculated.
2.4. Whole cell adenylyl cyclase activity
Whole cell AC activity was measured as previously described
[15,16]. Brie£y, cells loaded with 0.5 mCi of [3H]adenine were washed
in assay medium containing IBMX and stimulated for 30 min with
agonist. The reaction was stopped with a TCA solution containing
ATP and cAMP. cAMP was separated from the other adenosine
metabolites by means of double column chromatography on Dowex
followed by alumina.
Concentration-response curves to UK14304 and oxymetazoline
were performed in the presence of 50 WM forskolin. In assays with
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cholera toxin only the e¡ect of maximal doses of each compound (i.e.
1U1034 M) was assessed.
2.5. Analysis of the data
Data are expressed as % of inhibition or stimulation of forskolin-
induced production of cAMP. Concentration-response curves
were ¢tted using Kaleidagraph according to the equation:
m13(((m13m6)*(m0^m2))/((m0^m2)+(m3^m2))) where m6 is the
maximum inhibition (or stimulation), m2 the slope of the curve, m1
the origin of the curve and m3 represents the EC50 value.
3. Results
Comparisons were made between parental Rat-1 ¢broblasts
and clones derived from these cells which express either the
porcine K2A-adrenoceptor (clone ‘Tag WT’ [13]) or a fusion
protein between the K2A-adrenoceptor and a pertussis toxin-
resistant mutant (C351G) of the K subunit of Gi1 (clone ‘Ragi
77’ [12]).
Saturation binding studies using the potent and highly se-
lective K2A-adrenoceptor antagonist [3H]RS-79948-197 [14]
showed that it was impossible to detect any expression
of the receptor in the parental cell line but that clone Tag
WT and clone Ragi 77 expressed respectively some
108 000 þ 10 000 and 104 000 þ 13 000 copies per cell.
Intact cells were labelled overnight with [3H]adenine (0.5
WCi/ml) and regulation of forskolin-stimulated AC activity
by varying concentrations of UK14304 subsequently meas-
ured. As anticipated, UK14304 had no e¡ect on forskolin-
stimulated AC activity in the parental cell line (Fig. 1a). By
contrast, in cells expressing the isolated K2A-adrenoceptor,
UK14304 produced a biphasic response. Low concentrations
of UK14304 induced a marked, concentration-dependent, in-
hibition (IC50 = 2.9U10310 M) leading to a maximum of 70%
reduction of the forskolin-stimulated AC activity at 1038 M
UK14304. Addition of higher concentrations of UK14304 re-
sulted in a reversal of this e¡ect, such that no inhibition was
observed at concentrations above 1036 M (Fig. 1a).
In cells expressing the K2A-adrenoceptor-Gi1K fusion pro-
tein, the e¡ect of UK14304 was very di¡erent. Clear concen-
tration-related inhibition of forskolin-induced AC activity was
observed but with lower potency (IC50 = 1.2U1038 M). How-
ever, even at concentrations up to 1034 M there was no in-
dication of a reversal of the inhibition (Fig. 1a).
In our previous work with this cell line expressing the K2A-
adrenoceptor-Gi1K fusion protein we demonstrated that the
endogenous Gi G protein was responsible for all the inhibition
of forskolin-stimulated AC activity rather than the receptor-
linked C351G-Gi1K [12]. Following pertussis toxin-treatment
of the cells to cause ADP-ribosylation of the endogenous Gi-
population, in clone Tag WT expressing the porcine K2A-adre-
noceptor alone, UK14304 was unable to modify AC activity
at low concentrations (under 1038 M) but at higher concen-
trations, a very substantial stimulation of forskolin-ampli¢ed
AC activity (routinely 5^6-fold) was noted with an EC50 of
5U1037 M (Fig. 1b). As anticipated, pertussis toxin treatment
did not uncover such an e¡ect of UK14304 in parental Rat-1
¢broblasts. Equally, however, although abolishing the inhib-
itory regulation of AC activity in cells expressing the K2A-
adrenoceptor-Gi1K fusion protein, pertussis toxin treatment
also failed to result in stimulation of AC activity in response
to high concentrations of UK14304 (Fig. 1b).
Oxymetazoline is a selective, but partial, agonist of the K2A-
adrenoceptor [17]. This compound was again without e¡ect on
forskolin-ampli¢ed AC activity in membranes of parental
Rat-1 ¢broblasts (Fig. 2a). Low concentrations of oxymetazo-
line (IC50 = 4.2U10310 M) produced a large inhibition (75%)
(Table 1) of such activity in cells expressing the isolated K2A-
adrenoceptor but higher concentrations of this agonist were
unable to produce reversal of the inhibition in the manner
observed for UK14304 (Fig. 2a). In RAGI 77 cells expressing
the K2A-adrenoceptor-Gi1K fusion protein, inhibition of the
forskolin-ampli¢ed AC activity was observed over the full
range of concentrations of oxymetazoline. However, unlike
UK14304, the maximal degree of inhibition in response to
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Fig. 1. The e¡ects of UK14304 on forskolin-stimulated adenylyl cy-
clase activity. Concentration-e¡ect curves to measure the capacity of
UK14304 to regulate forskolin (50 WM)-ampli¢ed adenylyl cyclase
activity were performed on untreated cells (panel a) or following
pretreatment of the cells with pertussis toxin (25 ng/ml, 16 h) (panel
b), in Rat-1 ¢broblasts (triangles), Tag WT cells (circles) and clone
Ragi 77 cells (squares).
Table 1
EC50 and maximal e¡ects for UK14304 and oxymetazoline for Gi and/or Gs coupling
Cell line UK14304 Oxymetazoline Receptors/cell
TagWT (Gi) 2.9U10310 M (371%) 4.2U10310 M (375%) 108 000 þ 10 000
TagWT (Gs) 5 U1037 M (+527%) 7.5U1037 M (+30%)
Ragi 77 (Gi) 1.2U1038 M (364%) 1.1U1038 M (325%) 104 000 þ 13 000
Receptor number/cell was obtained in cells which had not been treated with pertussis toxin or cholera toxin.
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oxymetazoline was substantially poorer (25%) (Table 1) and a
lower potency of the compound (IC50 = 1.1U1038 M) was
observed. Following pertussis toxin treatment, oxymetazo-
line-mediated inhibition of forskolin-ampli¢ed AC activity
was attenuated in cells expressing either the isolated K2A-adre-
noceptor or the K2A-adrenoceptor-Gi1K fusion protein (Fig.
2b). Furthermore, oxymetazoline, at high concentrations,
was able to induce only a trivial stimulation of forskolin-am-
pli¢ed AC activity, in cells expressing the isolated K2A-adre-
noceptor (Fig. 2b).
Cholera toxin catalyses ADP-ribosylation of GsK resulting
in persistent activation of this protein and its subsequent in-
sensitivity to the e¡ects of receptor agonists. Following treat-
ment of cells with cholera toxin, 1U1034 M UK14304 caused
marked inhibition of forskolin-ampli¢ed AC activity (Fig. 3)
in the cell lines expressing both the isolated K2A-adrenoceptor
or the K2A-adrenoceptor-Gi1K fusion protein. Oxymetazoline
also caused inhibition of AC activity under these conditions in
both cell types, although as anticipated from the lower e⁄cacy
described in untreated conditions with the fusion construct, a
lower maximal e¡ect was observed at the K2A-adrenoceptor-
Gi1K fusion protein than at the isolated K2A-adrenoceptor
(Fig. 3).
4. Discussion
The results presented herein demonstrate, for the ¢rst time,
that although the porcine K2A-adrenoceptor has the capability
to interact in an agonist-dependent manner with both endog-
enously co-expressed Gi and Gs, and thus biphasically regu-
late AC activity, this is selectively modulated following con-
struction of a fusion protein in which the K subunit of a
pertussis toxin-resistant mutant of Gi1 is linked in frame to
the C-terminal of the receptor.
Following stable expression of this fusion protein in Rat-1
¢broblasts we have previously demonstrated that agonists are
able to activate both endogenous and the fusion protein-
linked Gi [12]. This was assessed by agonist stimulation of
membrane high a⁄nity GTPase activity which was partially
pertussis toxin-sensitive and partly resistant to the actions of
this ADP-ribosyltransferase. Despite the capacity of the re-
ceptor in the fusion protein to cause guanine nucleotide ex-
change and hydrolysis in both the receptor-linked and free
endogenous pool of Gi, the observed agonist-mediated inhib-
ition of AC activity was transduced only via the endogenous
Gi as the e¡ect was completely attenuated by pertussis toxin
treatment [12].
Stable expression of either the isolated K2A-adrenoceptor or
the K2A-adrenoceptor-Gi1K fusion protein to similar levels has
now allowed examination of the relative capacity of the re-
ceptor to interact with Gi and Gs and thus regulate AC ac-
tivity. As previously reported for the human K2A-adrenocep-
tor [7,18], at low concentrations the agonist UK14304
produced inhibition of forskolin-ampli¢ed AC activity in in-
tact cells expressing the porcine K2A-adrenoceptor. As might
be anticipated, this e¡ect was attenuated by prior treatment of
the cells with pertussis toxin. At concentrations of UK14304
greater than 1U1037 M, the inhibitory regulation was re-
versed and indeed, following pertussis toxin treatment to pre-
vent productive interaction of the receptor with Gi the stim-
ulation of AC activity produced by activation of GsK could be
easily observed. Interestingly, in cells expressing the K2A-adre-
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Fig. 3. The e¡ects of cholera toxin on agonist regulation of adenylyl
cyclase activity. Cells (Rat-1 ¢broblasts (open bars), Tag WT
(hatched bars) and Ragi 77 (stippled bars)) were either untreated
(left hand side) or treated with cholera toxin (Ctox) (1 Wg/ml, 16 h)
(right hand side). Subsequently the e¡ects of UK14304 (panel a)
and oxymetazoline (panel b) (each at 1U1034 M) on forskolin-
stimulated adenylyl cyclase activity were measured.
Fig. 2. The e¡ects of oxymetazoline on forskolin-stimulated adenylyl
cyclase activity. Concentration-e¡ect curves to measure the capacity
of oxymetazoline to regulate forskolin (50 WM)-ampli¢ed adenylyl
cyclase activity were performed on untreated cells (panel a) or fol-
lowing pretreatment of the cells with pertussis toxin (panel b), in
Rat-1 ¢broblasts (triangles), Tag WT cells (circles) and clone Ragi
77 cells (squares).
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noceptor-Gi1K fusion protein we were unable to produce any
evidence of the capacity of UK14304 to activate GsK and then
stimulate AC activity, even following pertussis toxin treat-
ment, which allowed this aspect of the function of UK14304
at the isolated receptor to be observed more easily (see Fig. 1).
It was also noticeable that higher concentrations of
UK14304 were required to produce half-maximal inhibition
of forskolin-ampli¢ed AC activity in the cells expressing the
fusion protein. One obvious interpretation of this ¢nding is
that the fusion protein is less e¡ective in activating the endog-
enous pool of Gi than is the isolated receptor and therefore
agonist occupancy of a greater number of the receptor sites is
required to produce the same degree of inhibition. By com-
paring agonist-induced stimulation of the GTPase activity of
the fusion protein associated G protein and the endogenous G
protein population, we have previously calculated that the
fusion protein is able to activate some 6 mol Gi/mol of re-
ceptor [12]. Although we do not have suitable means to pro-
duce an equivalent analysis for the isolated receptor, the re-
sults presented herein indicate that this ratio may be
substantially higher.
Eason and colleagues have previously indicated that not all
agonists at the human K2A-adrenoceptor are able to produce
both inhibitory and stimulatory regulation of AC activity [19].
They reported that oxymetazoline is able to produce only the
inhibitory phase of the signal. We thus examined the e¡ects of
this agonist on the regulation of forskolin-ampli¢ed AC ac-
tivity in both cell lines. In that expressing the isolated recep-
tor, inhibition was observed in a concentration-dependent
manner, which reached the same extent as produced by
UK14304. However, no matter what the concentration used,
no reversal of this e¡ect was observed (Fig. 2). After pertussis
toxin treatment, to remove the interaction of the receptor with
endogenous Gi, only a small interaction of the receptor with
Gs could be induced by oxymetazoline (30% stimulation of
AC activity vs. 530% observed with UK14304). Again, results
were di¡erent in the cells expressing the K2A-adrenoceptor-
Gi1K fusion protein. As anticipated, no evidence for interac-
tion of this construct with GsK could be obtained. A concen-
tration-dependent inhibition of forskolin-ampli¢ed AC activ-
ity could be recorded. However, this also displayed a
signi¢cantly greater EC50 than for the isolated receptor and
now the maximal degree of inhibition was much lower than
that produced either by UK14304 at the fusion construct or
indeed by oxymetazoline in the cells expressing the receptor
alone. This is likely to re£ect a lower e¡ectiveness of the
coupling of the fusion protein to the endogenous Gi popula-
tion compared to that produced by the isolated receptor.
In many cell systems AC is expressed at relatively low levels
when compared to those of the G proteins that regulate this
e¡ector (see [20] for review). As such, maximal regulation of
AC activity can routinely be produced by activation of only a
small fraction of the cellular G protein population. As the
levels of expression of both the isolated receptor and the fu-
sion protein are high and equivalent in our cell systems (Table
1), UK14304 was able to activate enough endogenous Gi in
both cell types to induce the same maximal degree of inhib-
ition of the forskolin-stimulated AC activity. By contrast, as
oxymetazoline is known as a partial agonist at the K2A-adre-
noceptor [17], good inhibition of the AC activity in the cells
expressing the isolated receptor could be reached. However,
because of a possible lower quantitative capacity of the fusion
protein to catalytically activate endogenous Gi, then only par-
tial inhibition could be achieved in the cells expressing the
fusion protein, even at high concentrations of oxymetazoline
where the entire population of receptors should be occupied.
The molecular basis for these observations remains to be
elucidated but two possibilities can be considered. The ¢rst is
that the construction of the fusion protein induced some phys-
ical constraint to the receptor such that sites for interaction
with GsK are masked whereas those for interaction with GiK
are perturbed to a lesser degree. Analysis of elements of the
second and third intracellular loop of the human K2A-adreno-
ceptor using chimaeric receptor constructs have indeed indi-
cated that resolvable domains are central for e¡ective inter-
actions with these two classes of G proteins [21]. Furthermore,
a mutagenesis study [22] showed that mutation of Asp130 in
the K2A-adrenoceptor ablated agonist-dependent stimulation
of AC activity but not the inhibition. Overall these results,
as well as those of Eason et al. [19], indicate that the binding
of di¡erent agonists within the receptor binding pocket may
cause di¡erent conformational changes and thus di¡erent de-
grees of activation of Gi and Gs.
Secondly, it has become steadily more clear in recent times
that compartmentalisation of signalling elements within spe-
ci¢c domains of the plasma membrane is an important con-
tributor to the e¡ectiveness and speci¢city of signal transduc-
tion processes [23]. It is clearly possible that di¡erences in
plasma membrane distribution of the isolated K2A-adrenocep-
tor and the K2A-adrenoceptor-C351G Gi1K fusion protein lim-
it the availability and access of these two forms of the recep-
tor to the endogenous G protein pools. Future studies will
explore these possibilities.
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